Trials / Withdrawn
WithdrawnNCT00576225
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol > 25 pg/mL
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- CTI BioPharma · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels \>30 pg/ml.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT-2103/carboplatin | CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles. |
| DRUG | paclitaxel/carboplatin | Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles. |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2010-04-05
- Completion
- 2010-04-05
- First posted
- 2007-12-19
- Last updated
- 2020-10-19
Locations
44 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00576225. Inclusion in this directory is not an endorsement.